Shots: The companies collaborated to evaluate the safety, PK & antiviral activity of ATI-2173, vebicorvir & TDF in an ongoing P-IIa ANTT201 trial in 10 treatment naïve or off-treatment HBeAg […]readmore
Tags : Chronic Hepatitis B Virus Infection
Shots: Dicerna to receive $200M up front and up to $1.47B development, regulatory and commercial milestones and royalties based on the sales of DCR-HBVS. Roche to get WW license to […]readmore
Shots: Ionis to receive ~$262M milestones including $25M license fee with royalties on sales of products. GSK to exercise its option to license program following positive P-II results and will […]readmore